Researchers at Weill Cornell Medicine found that cancer often releases molecules into the bloodstream that pathologically modify the liver, sending it into an inflammatory state, causing fat accumulation, and disrupting its typical detoxification processes. This finding sheds light on one of
A new nutrition source for pancreatic cancer cells has been discovered by researchers at the University of Michigan Rogel Cancer Centre. Uridine is a substance that provides insight into both biological processes and potential treatment paths.
The findings, published May 8 in Nature Medicine, suggest that AI-based population screening could be valuable in finding those at elevated risk for the disease and could expedite the diagnosis of a condition found all too often at advanced stages when treatment is less effective and outc
A novel cell signalling route was discovered by researchers at the Johns Hopkins Kimmel Cancer Centre that may one day be used as a therapeutic target for people with aggressive pancreatic cancer.
Despite advances in pancreatic cancer treatment, only around 9% of patients live beyond five years. Researchers have failed to identify genetic distinctions that explain why some patients live for a long time and others do not, so they have moved their focus to the gut microbiome.
A Duke Health research team has uncovered a collection of biomarkers that might help determine whether pancreatic cysts are likely to develop into cancer or stay benign.
Cedars-Sinai Cancer Center researchers confirmed in a large-scale nationwide survey that pancreatic cancer rates are growing and rising faster among younger women, than males of the same age. Their findings were published in the peer-reviewed journal Gastroenterology.
In Phase 3 clinical trial for metastatic pancreatic ductal adenocarcinoma, a four-drug chemotherapy treatment led to a longer overall survival than a two-drug combination.
The source of tumour cell resistance to immunotherapy was identified by a recent study that examined the pancreatic cancer tumour microenvironment, and novel therapeutic approaches were developed as a result.
In the Phase 3 clinical trial for metastatic pancreatic ductal adenocarcinoma, a four-drug chemotherapy treatment led to a longer overall survival than a two-drug combination.
A molecular mechanism important for the development of pancreatic cancers has been found by researchers at the University of California, San Diego School of Medicine. The mechanism could possibly contribute to the disease's great resistance to treatment and proclivity for metastasis.